Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 611 to 620 of 2194 total matches.

Namzaric - A Combination of 2 Old Drugs for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 20, 2015  (Issue 1473)
or reverse the underlying neurodegenerative process.1 Many patients with moderate to severe AD are treated ...
The FDA has approved Namzaric (Forest), a fixed-dose combination of extended-release (ER) memantine (Namenda XR), an NMDA-receptor antagonist, and donepezil (Aricept, and generics), an acetylcholinesterase inhibitor, for treatment of moderate to severe Alzheimer's type dementia in patients previously stabilized on both drugs. The patent for Namenda has recently expired and generic formulations of memantine 5- and 10-mg tablets have been approved.
Med Lett Drugs Ther. 2015 Jul 20;57(1473):105-6 | Show Introduction Hide Introduction

Liletta - A Third Levonorgestrel-Releasing IUD

   
The Medical Letter on Drugs and Therapeutics • Jul 06, 2015  (Issue 1472)
IUDs (see Table 1), but the manufacturer offers programs that significantly reduce the cost ...
The FDA has approved Liletta, an intrauterine device (IUD) that releases the synthetic progestin levonorgestrel, for prevention of pregnancy for up to 3 years. The fourth IUD to be approved in the US, and the third that releases levonorgestrel, Liletta is comarketed by Actavis and Medicines360, a nonprofit women's health pharmaceutical company. The wholesale cost of Liletta is similar to that of other IUDs (see Table 1), but the manufacturer offers programs that significantly reduce the cost for commercially-insured patients and clinics serving low-income women.
Med Lett Drugs Ther. 2015 Jul 6;57(1472):99-100 | Show Introduction Hide Introduction

Ryanodex - A New Dantrolene Formulation for Malignant Hyperthermia

   
The Medical Letter on Drugs and Therapeutics • Jul 06, 2015  (Issue 1472)
for treatment of malignant hyperthermia for many years.1 THE NEW FORMULATION — Ryanodex is available ...
The FDA has approved a new IV formulation of dantrolene (Ryanodex – Eagle) for prevention and treatment of malignant hyperthermia in adults and children. The new formulation requires fewer vials, less fluid volume, and less time for preparation and administration than other available IV dantrolene products (Dantrium, Revonto).
Med Lett Drugs Ther. 2015 Jul 6;57(1472):100 | Show Introduction Hide Introduction

Eliglustat (Cerdelga) - An Oral Drug for Gaucher Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 06, 2015  (Issue 1472)
of adults with type 1 Gaucher disease. Eliglustat is metabolized primarily by CYP2D6. Because patients who ...
The FDA has approved eliglustat (Cerdelga – Genzyme), an oral glucosylceramide synthase inhibitor, for treatment of adults with type 1 Gaucher disease. Eliglustat is metabolized primarily by CYP2D6. Because patients who are CYP2D6 ultra-rapid metabolizers may not achieve therapeutic concentrations and a specific dosage cannot be recommended for indeterminate metabolizers, the FDA has approved the drug only for patients who are extensive, intermediate, or poor metabolizers of CYP2D6.
Med Lett Drugs Ther. 2015 Jul 6;57(1472):e100-101 | Show Introduction Hide Introduction

Liraglutide (Saxenda) for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015  (Issue 1471)
Liraglutide (Saxenda) for Weight Loss The injectable glucagon-like peptide-1 (GLP-1) receptor agonist ...
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide, previously approved by the FDA for treatment of type 2 diabetes as Victoza, has now also been approved at a higher dose as Saxenda (Novo Nordisk) for chronic weight management in adults with a BMI ≥30, or a BMI ≥27 with a weight-related comorbidity such as hypertension, dyslipidemia, or diabetes.
Med Lett Drugs Ther. 2015 Jun 22;57(1471):89-90 | Show Introduction Hide Introduction

Which PPI?

   
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015  (Issue 1471)
Which PPI? An article published in the New York Times on May 1, 2015 listed the 10 drugs on which ...
An article published in the New York Times on May 1, 2015 listed the 10 drugs on which Medicare Part D spent the most in 2013. The most costly ($2.53 billion) was the proton pump inhibitor (PPI) Nexium (esomeprazole magnesium), which has recently become available generically.
Med Lett Drugs Ther. 2015 Jun 22;57(1471):91 | Show Introduction Hide Introduction

Droxidopa (Northera) for Neurogenic Orthostatic Hypotension

   
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015  (Issue 1471)
used (off-label) to treat symptomatic NOH include fludrocortisone and pyridostigmine.1 MECHANISM ...
The FDA has approved droxidopa (Northera – Lundbeck) for oral treatment of adults with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, or pure autonomic failure), dopamine beta-hydroxylase deficiency, or nondiabetic autonomic neuropathy. This is the first approval for droxidopa in the US. It has been available in Japan for use in NOH since 1989.
Med Lett Drugs Ther. 2015 Jun 22;57(1471):92-3 | Show Introduction Hide Introduction

Bellafill for Acne Scars

   
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015  (Issue 1471)
12 months.1 ADVERSE EFFECTS — Swelling, redness, pain, bruising, lumps/bumps, itching ...
Bellafill (Suneva), a dermal filler approved earlier for correction of nasolabial folds, has now also been approved by the FDA for correction of moderate to severe, atrophic, distensible facial acne scars on the cheek in adults ≥21 years old. It is the only dermal filler approved in the US for correction of facial acne scars.
Med Lett Drugs Ther. 2015 Jun 22;57(1471):93-4 | Show Introduction Hide Introduction

In Brief: Ketoacidosis with SGLT2 Inhibitors

   
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015  (Issue 1471)
) inhibitor for treatment of type 2 diabetes may lead to ketoacidosis.1 Three SGLT2 inhibitors ...
The FDA has warned that use of an SGLT2 (sodium-glucose co-transporter 2) inhibitor for treatment of type 2 diabetes may lead to ketoacidosis.1 Three SGLT2 inhibitors, canagliflozin (Invokana, Invokamet), dapagliflozin (Farxiga, Xigduo XR), and empagliflozin (Jardiance, Glyxambi), are approved for treatment of type 2 diabetes in the US. Between March 2013 and June 2014, 20 cases of ketoacidosis requiring emergency room visits or hospitalization were reported in patients who had recently started taking an SGLT2 inhibitor; the median time to onset of symptoms after initiation of therapy was 2...
Med Lett Drugs Ther. 2015 Jun 22;57(1471):94 | Show Introduction Hide Introduction

Addendum: Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC

   
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015  (Issue 1471)
) was published in the most recent issue of The Medical Letter (June 8, 2015),1 some new data became available ...
After our article on nivolumab (Opdivo – BMS) for treatment of metastatic melanoma and metastatic squamous non-small cell lung cancer (NSCLC) was published in the most recent issue of The Medical Letter (June 8, 2015),1 some new data became available supporting the efficacy of the drug in previously untreated melanoma and previously treated nonsquamous NSCLC.MELANOMA – In a double-blind trial, 945 patients with previously untreated, unresectable stage III or IV melanoma were randomized to receive ipilimumab, nivolumab, or combination therapy with ipilimumab and nivolumab. Progression-free...
Med Lett Drugs Ther. 2015 Jun 22;57(1471):94 | Show Introduction Hide Introduction